Bilateral PENG Block for Total Vaginal Hysterectomy (PENG)
Bilateral Ultrasound-Guided Pericapsular Nerve Group (PENG) Block for Postoperative Analgesia After Total Vaginal Hysterectomy Under General Anesthesia: A Prospective Exploratory Pilot Study
This prospective, single-arm pilot study will evaluate the feasibility, safety, and preliminary analgesic outcomes of bilateral pericapsular nerve group (PENG) blocks in adult patients undergoing total vaginal hysterectomy (TVH) under general anesthesia at UI Health. The study will target 25 evaluable subjects, with enrollment of up to 30 subjects to account for withdrawal or incomplete data. Following induction of general anesthesia, subjects will receive ultrasound-guided bilateral PENG blocks using 20 mL of 0.2% ropivacaine per side, in addition to standard perioperative analgesic management. Outcomes will include postoperative pain scores, perioperative analgesic requirements, motor weakness and ambulation, postoperative nausea and vomiting, PACU recovery and discharge, and adverse events. Data from this pilot study will be used to characterize the feasibility and safety of the intervention and to inform the design of a future controlled study.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase temprana 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Alexandra Barabanova, MS
- Número de teléfono: 312-355-5733
- Correo electrónico: barabano@uic.edu
Copia de seguridad de contactos de estudio
- Nombre: Kantarakorn Unchiti, MD PhD
- Correo electrónico: Kantarakorn.u@gmail.com
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18 years or older
- Scheduled to undergo elective total vaginal hysterectomy under general anesthesia
- Planned postoperative recovery in the PACU
- Able to provide written informed consent
- Able to understand and report postoperative pain using the NRS (0-10)
Exclusion Criteria:
Known allergy or hypersensitivity to the local anesthetic selected for the PENG block or to other amide local anesthetics
2. Infection, cellulitis, open wound, or other active skin or soft-tissue infection at or near the proposed block site
3. Known clinically significant coagulopathy, thrombocytopenia, or anticoagulant or antiplatelet therapy that, according to institutional guidelines or the judgment of the treating anesthesiologist, would increase the risk associated with performance of the PENG block
4. Pre-existing clinically significant lower-extremity neurologic or motor deficit that may increase the risk associated with the block or interfere with postoperative assessment of motor or neurologic adverse events
5. Anatomical abnormality, prior surgery involving the proposed block region, or other condition that, in the judgment of the treating anesthesiologist, would prevent adequate visualization of relevant anatomy or safe performance of the PENG block
6. Any medical condition or clinical circumstance that, in the judgment of the treating anesthesiologist or investigator, would increase the risk associated with bilateral PENG block or administration of the study local anesthetic
7. Planned neuraxial anesthesia or another regional anesthetic technique expected to provide perioperative analgesia and interfere with assessment of the study intervention
8. Receipt or planned receipt of additional local anesthetic that would result in a total local anesthetic dose considered unsafe by the treating anesthesiologist
9. Inability to reliably communicate postoperative pain using the NRS
10. Pregnancy
11. Prisoner status
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: PENG Block
Following induction of general anesthesia and prior to surgical positioning, participants will receive bilateral ultrasound-guided PENG blocks |
After negative aspiration and confirmation of appropriate needle position, 20 mL of 0.2% ropivacaine will be administered on each side, for a total volume of 40 mL and a total ropivacaine dose of 80 mg |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative pain intensity during the PACU stay
Periodo de tiempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Assessed using the Numeric Rating Scale (NRS, 0-10) at PACU arrival (once awake and able to provide a reliable assessment). |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants requiring rescue opioid analgesia during the PACU stay
Periodo de tiempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
|
Location of postoperative pain
Periodo de tiempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Self-reported by the participant at each PACU assessment and categorized as deep pelvic/vaginal, perineal/introital, suprapubic, groin/hip, medial thigh, or lower back pain |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
Cutaneous sensory block, at each PACU pain-assessment timepoint
Periodo de tiempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
assessed bilaterally in the femoral, saphenous, obturator, lateral femoral cutaneous, genitofemoral (femoral branch), and ilioinguinal/iliohypogastric territories using a 3-point scale |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
Correspondence between the anatomical territories in which sensory block is demonstrated and the anatomical location of reported postoperative pain
Periodo de tiempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
|
Incidence of postoperative nausea and vomiting during the PACU stay
Periodo de tiempo: Any time during PACU stay
|
Any time during PACU stay
|
|
|
Duration of PACU stay
Periodo de tiempo: PACU Stay
|
PACU Stay
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Lower-extremity motor weakness following bilateral PENG block, a
Periodo de tiempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Assessed bilaterally by knee extension (quadriceps, femoral nerve) and hip adduction (adductors, obturator nerve) and graded using the Medical Research Council (MRC) 0-5 scale, referenced to the participant's own preoperative baseline examination |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
|
Persistence of sensory or motor block at PACU discharge
Periodo de tiempo: PACU discharge
|
Defined as any territory scored as reduced or absent, or any MRC grade below the participant's preoperative baseline, at the final PACU assessment |
PACU discharge
|
|
Falls or near-falls
Periodo de tiempo: The postoperative observation period in PACU
|
The postoperative observation period in PACU
|
|
|
Signs or symptoms of local anesthetic systemic toxicity
Periodo de tiempo: Starting from the block time until 30 min after the block
|
Cardiovascular System Symptoms
|
Starting from the block time until 30 min after the block
|
|
New lower-extremity sensory or neurological symptoms following the block
Periodo de tiempo: 30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Weakness in lower-extremity and numbness |
30 minutes after PACU arrival, 60 minutes after PACU arrival, and at PACU discharge
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Stephan Cohn, MD, University of Illinois Chicago
Publicaciones y enlaces útiles
Publicaciones Generales
- Ciftci B, Ahiskalioglu A, Altintas HM, Tekin B, Sakul BU, Alici HA. A possible mechanism of motor blockade of high volume pericapsular nerve group (PENG) block: A cadaveric study. J Clin Anesth. 2021 Nov;74:110407. doi: 10.1016/j.jclinane.2021.110407. Epub 2021 Jun 24. No abstract available.
- Pai P, Amor D, Lai YH, Echevarria GC. Use and Clinical Relevancy of Pericapsular Nerve Block (PENG) in Total Hip Arthroplasty: A Systematic Review and Meta-analysis. Clin J Pain. 2024 May 1;40(5):320-332. doi: 10.1097/AJP.0000000000001196.
- ACOG Committee Opinion No. 750: Perioperative Pathways: Enhanced Recovery After Surgery. Obstet Gynecol. 2018 Sep;132(3):e120-e130. doi: 10.1097/AOG.0000000000002818.
- Huang Y, Lu Y, Wang J, Lu Q, Bao HF, Liu L, Dong CS. Effect of Pericapsular Nerve Group Block with Different Concentrations and Volumes of Ropivacaine on Functional Recovery in Total Hip Arthroplasty: A Randomized, Observer-Masked, Controlled Trial. J Pain Res. 2024 Feb 14;17:677-685. doi: 10.2147/JPR.S445000. eCollection 2024.
- Wegmann T. [Detection and treatment of rabies in humans]. Schweiz Med Wochenschr. 1966 Jun 11;96(23):743-6. No abstract available. German.
- Hin PC. Laparoscopic-assisted gastrostomy in 26 patients: indications and outcome at 2 years. J Laparoendosc Surg. 1996 Feb;6(1):25-8. doi: 10.1089/lps.1996.6.25.
- Slopnick EA, Sears SB, Chapman GC, Sheyn DD, Abrams MK, Roberts KM, Pollard R, Mangel J. Pudendal Nerve Block Analgesia at the Time of Vaginal Surgery: A Randomized, Double-Blinded, Sham-Controlled Trial. Urogynecology (Phila). 2023 Oct 1;29(10):827-835. doi: 10.1097/SPV.0000000000001351. Epub 2023 Apr 4.
- Goidescu OC, Dogaru IA, Badea TG, Enyedi M, Enciu O, Gheoca Mutu DE, Filipoiu FM. The distribution of the inferior hypogastric plexus in female pelvis. J Med Life. 2022 Jun;15(6):784-791. doi: 10.25122/jml-2022-0145.
- Hartmann F. [75th Anniversary of professor Dr. Rudolf Schoen]. Med Klin. 1967 Feb 24;62(8):314-6. No abstract available. German.
- Aurore V, Rothlisberger R, Boemke N, Hlushchuk R, Bangerter H, Bergmann M, Imboden S, Mueller MD, Eppler E, Djonov V. Anatomy of the female pelvic nerves: a macroscopic study of the hypogastric plexus and their relations and variations. J Anat. 2020 Sep;237(3):487-494. doi: 10.1111/joa.13206. Epub 2020 May 19.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2026-1073
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
To avoid breeches of privacy and confidentiality
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .